BIS Research ( Business Intelligence and Strategy Research)

  The strategies followed by various prominent companies to sustain the competition and expand their market share has been varying from mergers and acquisitions (M&A) to collaborations and partnerships. In the past three years (January 2017-September 2020), the market witnessed approximately eight M&A activities, seven partnerships, and alliances (collaborations, joint ventures, and other agreements), one business expansion, and four other developments. Among the different key developments, M&A activities constitute the dominant contributor’s strategies, followed by partnership and alliances. The global bioengineered skin substitutes market is dominated by juggernauts including AbbVie, Inc., Integra LifeSciences Corporation, Smith & Nephew plc, and Stryker Corporation, and other medium and small-medium enterprises that are offering wide ranges of bioengineered skin substitute products in the market. Several companies are attempting to enter the market and sustain the

  The human genome comprises DNA sequences that provide a code for the synthesis and regulation of an estimated 20,000 proteins. However, there is a natural variation between individuals’ genomes that leads to differences in structure, function, and production of proteins. Precision medicine is a concept of identifying such variations in specific genes that affect the health response to interventions. Contrary to the empiric medicine method, the precision medicine approach begins with testing and analysis of the patient to pre-determine the best fit mode of treatment for the patient. Following the accomplishment of the human genome project, there had been significant progress in characterizing the human epigenome, proteome, metabolome, and pharmacogenomics that has led to the evolution of customized healthcare for the individual, especially patients suffering from cancer.  View BIS Research Report on  Oncology Precision Medicine Market Furthermore, germline mutations and somatic mutati

  As depicted, the genome sequencing cost is decreasing while the production (TB) is increasing. It is expected that the cost of genome sequencing would ultimately drop to as low as $100 by 2025. As a result, it is highly possible that the use of genome sequencing will become more widely adopted and integrated into regular clinical practice, thereby bolstering the scope of companion diagnostic usage across the healthcare continuum for treatment preferences. As per BIS Research analysis, the global companion diagnostics market is projected to reach $7,536.7 million by 2030 from $1,764.7 million in 2019, at a CAGR of 12.45% during the forecast period of 2020-2030. This growth has been primarily attributed to the major drivers in this market, which comprise the growing incidence of cancer within the global population that has intensified the demand for better treatment assurance for all cancer types. Additionally, the growing demand for personalized medicine and the regulatory mandate

  Owing to the market availability of large number of liquid biopsy technologies, the liquid biopsy segment currently accounts for a dominating share in the global minimally invasive biopsy technologies market . However, the market growth in the segment can be attributed to the increasing demand for liquid biopsy and the strong product pipeline. For instance, CNI Second Opinion by Chronix Biomedical is presently under development and is expected to get launched during the forecast period 2019-2030. Owing to a widespread market presence of leading players and the huge prevalence of cancer, North America presently holds a major share in the global minimally invasive biopsy technologies market. According to the World Cancer Research Fund (WCRF), with an estimated 2 million cases in 2018, lung cancer is the most commonly occurring cancer in men and third-most commonly occurring cancer in women. Due to the widespread presence of cancer, the manufacturers including Biocept, Inc., Chronix B

  A paradigm shift in the dynamics of the market is expected to be witnessed around 2029 with the introduction of imaging solutions and single cell automated system in full scale. The leading players in the market are undertaking the necessary steps to tackle the shift in dynamics and sustain the competition. The global single cell sequencing market is divided into two main categories, instruments and consumables. Kits and consumables market share was valued at $727.2 million of the global single cell sequencing market value in 2018. Also, the kits and consumables is expected to witness impressive growth. The sub-segment is expected to grow with a CAGR of 15.67% during the forecast period 2019-2029. This reflects the dependency of single cell sequencing market on consumables, which is expected to continue to grow in the future. Single cell sequencing workflow is majorly divided into three segments: single cell isolation, single cell preparation, and single cell analysis. Presently

  The global 3D holographic display and services market has undergone significant and dynamic changes in the past decades, specifically with the introduction of a new type of display systems, such as 3D volumetric displays. With the increase in demand for display technologies, especially from the retail applications, such as POS display, product promotion, and product launch, the market for 3D holographic display and services are expected to grow at a rapid pace. The rapid adoption of new automotive technologies aligned with the ongoing trend for autonomous vehicles is also a huge factor contributing to the market for 3D holographic displays and services. AR-based HUDs, which can display useful information in holographic way, are key product types for the 3D holographic displays. These displays are not only used in the automotive industry but are also being deployed to the aerospace, defense & the aviation industry. The manufacturers are looking to explore the possibilities of the

  Non-communicable diseases (NCDS), such as cardiovascular disorders accounts for 17.9 million deaths in 2018, followed by cancers which accounted for 9.0 million deaths, respiratory diseases with 3.9 million deaths, and diabetes resulted in 1.6 million deaths. Other than cancer, infectious diseases, such as HIV/AIDS, tuberculosis, malaria, and HPV, are also responsible for the increasing death rates, especially in developing countries. In 2018, HIV accounted for 770,000 deaths globally, and more than 1.7 million people were newly infected. In 2018, there were an estimated 228 million cases of malaria worldwide.  View BIS Research Report:  Spatial Genomics and Transcriptomics Market According to the World Health Organization, there is a great disparity in the life expectancy rate in low-income countries than in high-income countries, such as Australia, Canada, the U.S., and the U.K. In 2016, life expectancy was 18.1 years lower in low-income countries (62.7 years) than in high-inco